Roth Capital Downgrades Salix Pharmaceuticals Ltd. (SLXP) to Hold
More News related to SLXP
- Salix Pharmaceuticals to Present at Piper Jaffray Conference
- Salix Pharma (SLXP) Completes 5.5M Common Offering at $21/Share
- Salix Pharmaceuticals, Ltd. Completes Sale of 6.325 Million Shares of Common Stock
- Salix (SLXP) December volatility at 56, January at 68, April at 73 into PDUFA
- Salix Pharma (SLXP) Prices 5.5M Share Offering
Roth Capital downgrades Salix Pharmaceuticals Ltd. (Nasdaq: SLXP) from Buy to Hold with an $8 price target.
Salix Pharmaceuticals, Ltd. develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases in the United States.
Related Categories
DowngradesStocks Mentioned
+0.32Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
